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ABSTRACT
Introduction Despite evidence that cardiac rehabilitation 
(CR) is an essential component of care for people with 
heart failure, uptake is low. A centre- based format 
is a known barrier, suggesting that home- based 
programmes might improve accessibility. The aim of 
SCOT: Rehabilitation EnAblement in CHronic Heart Failure 
(REACH- HF) is to assess the implementation of the REACH- 
HF home- based CR intervention in the context of the 
National Health Service (NHS) in Scotland.
This paper presents the design and protocol for this 
observational implementation study. Specific objectives of 
SCOT:REACH- HF are to: (1) assess service- level facilitators 
and barriers to the implementation of REACH- HF; (2) 
compare real- world patient and caregiver outcomes to 
those seen in a prior clinical trial; and (3) estimate the 
economic (health and social) impact of implementing 
REACH- HF in Scotland.
Methods and analysis The REACH- HF intervention 
will be delivered in partnership with four ‘Beacon sites’ 
across six NHS Scotland Health Boards, covering rural and 
urban areas. Health professionals from each site will be 
trained to facilitate delivery of the 12- week programme 
to 140 people with heart failure and their caregivers. 
Patient and caregiver outcomes will be assessed at 
baseline and 4- month follow- up. Assessments include 
the Minnesota Living with Heart Failure Questionnaire 
(MLHFQ), five- dimension EuroQol 5L, Hospital Anxiety and 
Depression Scale, and the Caregiver Burden Questionnaire. 
Qualitative interviews will be conducted with up to 20 
health professionals involved in programme delivery (eg, 
cardiac nurses, physiotherapists). 65 facilitator- patient 
consultations will be audio recorded and assessed for 
fidelity. Integrative analysis will address key research 
questions on fidelity, context and CR participant- related 
outcomes. The SCOT:REACH- HF findings will inform the 
future potential roll- out of REACH- HF in Scotland.
Ethics and dissemination The study has been given 
ethical approval by the West of Scotland Research Ethics 
Service (reference 20/WS/0038, approved 25 March 
2020). Written informed consent will be obtained from all 
participants. The study is listed on the ISRCTN registry with 
study ID ISRCTN53784122. The research team will ensure 
that the study is conducted in accordance with both 
General Data Protection Regulations and the University of 
Glasgow’s Research Governance Framework. Findings will 
be reported to the funder and shared with Beacon Sites, to 
facilitate service evaluation, planning and good practice. 
To broaden interest in, and understanding of REACH- 
HF, we will seek to publish in peer- reviewed scientific 
journals and present at stakeholder events, national and 
international conferences.
INTRODUCTION
Heart failure (HF) is both serious and 
common, and its prevalence is increasing.1 2 
Despite advances in care, people in Scotland 
with HF continue to have worse survival rates 
than those of some common cancers.3 HF 
often has a negative effect on health- related 
quality of life (HRQoL) for those living with 
it,1 4 and carries a high risk of hospitalisation, 
a major driver of the economic burden.1 5
Cardiac rehabilitation (CR) is highly 
effective, cost- effective and integral to 
comprehensive care of people with HF.6–8 
Self- care in HF is also widely acknowledged 
Strengths and limitations of this study
 ► A formal study of the implementation of a novel 
home- based cardiac rehabilitation programme for 
heart failure in the context of National Health Service 
Scotland.
 ► Study employs mixed methods which integrate 
quantitative and qualitative approaches to under-
stand the implementation process.
 ► Addresses home- based cardiac rehabilitation at a 
time of increased interest in, and need for, remote 
facilitation of care due to the COVID-19 pandemic.
 ► Although limited to four sites geographical sites, 
these sites incorporate a wide range of settings in-
cluding urban and rural populations.
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as important, and should also involve family/friends, 
and promote self- efficacy.9 A recent individual–partici-
pant data meta- analysis,7 and updated Cochrane review, 
show that, compared with no rehabilitation, CR partic-
ipation reduces the risk of all- cause hospitalisation and 
improves HRQoL (assessed using the MLHFQ).8 The 
2019 National Heart Failure Audit reported that referral 
for CR was associated with a 12% reduction in mortality.10
Despite this strong evidence, and national and inter-
national clinical guidelines recommending that anyone 
living with HF should receive CR, referral for and partici-
pation in CR remains low.8 The National Audit of Cardiac 
Rehabilitation (NACR) found that only 57% of people 
with HF in England, Wales and Northern Ireland (Scot-
tish data are not currently included in this audit) who 
were offered CR in 2018–2019 attended one or more 
sessions (email communication from NACR). Currently, 
most cardiac patients (77%) receive centre (hospital)- 
based, group CR.8 Travelling to centres and dislike of 
group exercise are key barriers to participation in centre- 
based programmes.6 10 11 That women, people from black 
and minority ethnic groups, and those living in high 
deprivation are less likely to attend centre- based CR,8 
indicates that centre- based approaches are exclusionary. 
Home- based CR thus offers a cost- effective approach 
to improving CR uptake by people with HF, resulting 
in better health and well- being outcomes. The 2020 
COVID-19 pandemic, and the policy by many countries 
of home lockdown to maintain social distancing, has 
dramatically underlined the urgent need for alternatives 
to centre- based models of healthcare provision.
We codeveloped (with clinicians/practitioners, people 
with health failure, their caregivers and service commis-
sioners) an evidence- based and theory- based, novel 
home CR intervention for people with HF: Rehabilitation 
EnAblement in CHronic Heart Failure (REACH- HF).12 A 
multicentre randomised trial demonstrated that the addi-
tion of REACH- HF to usual medical care resulted in a clin-
ically important improvement in HRQoL of people with 
HF, when compared with usual care alone.13 Economic 
modelling showed that the REACH- HF intervention to 
be both low- cost (at £417/patient) and cost effective.14 
However, there remains a paucity of data regarding 
the extent to which introducing home- based CR for 
HF increases CR uptake.6 15 Moreover, it is uncertain 
that the positive outcomes identified in the REACH- HF 
randomised controlled trial (RCT) can be replicated in a 
‘real- world’ setting, and what key considerations are with 
regards to embedding such an intervention in everyday 
practice.
At present, relatively few evidence- based healthcare 
interventions become embedded in routine clinical prac-
tice.16 Factors contributing to this include: weak external 
validity of efficacy trials; intervention developers’ lack 
of consideration for scale- up; trial design issues; and 
development of interventions that are overly theoret-
ical.17–19 Where implemented, evaluations often consider 
individual- level health professional performance, 
targeting knowledge, routines and attitudes.20 21 Indi-
viduals play a significant role in implementation, in that 
they dynamically engage with interventions while, to 
varying degrees, embodying their own interests and moti-
vations and those of their profession, organisation and 
culture.22 23 It is crucial also to understand community, 
organisational, system and policy- level influences on the 
embedding of innovative practice.22
Running parallel to a similar implementation study 
already underway in England and Northern Ireland,24 
our study seeks to understand the organisational and 
other wide- ranging influences affecting the implementa-
tion of REACH- HF in Scotland, in order to inform poten-
tial large- scale roll- out of the intervention. A key factor 
shaping implementation is that a given intervention may 
not produce the same effects when transferred from one 
context to another and, crucially, from a randomised 
trial to the real world. Target population characteristics 
may differ in key ways, such as geographical location 
(urban/rural) or relative deprivation. Moreover, there 
may be significant contextual differences between sites 
and teams delivering a healthcare intervention, such as 
the size of the team or familiarity with a given approach. 
Such contextual differences may produce adaptations in 
what is delivered and how (ie, impacting fidelity to the 
intervention design). This may in turn shape intervention 
results—including any proven benefit—when compared 
with an RCT.25 Adaptability to context may also impact 
the sustainability of an intervention, that is, the extent to 
which it is embedded in everyday practice.22
We draw specifically from UK Medical Research 
Council (MRC) guidance on evaluation of complex 
interventions, particularly using process evaluation meth-
odology.26 Process evaluation is an established means 
by which to understand implementation by assessing: 
fidelity (the degree to which the intervention was deliv-
ered as intended); context (barriers to and facilitators 
of implementation, including those that might explain 
variation in outcomes), and mechanisms of impact.23 As 
the mechanisms by which the REACH- HF intervention 
changes behaviour have been described and explored 
elsewhere,12 13 we focus here on fidelity and context in 
the new delivery setting. Integration of process and 
outcome data can generate better understanding of, for 
example, whether and how adaptations to implementa-
tion, or differences among sites, explains any observed 
variation in outcomes, as well as informing improvements 
for future roll- out.
METHODS AND ANALYSIS
Study design
A mixed- method implementation study comprises a 
multicentre prospective cohort study and nested process 
and economic evaluations.
The overarching aim of this study is to assess the real- 
world implementation REACH- HF for people living with 
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HF and their caregivers in Scotland. Our research ques-
tions are:
1. What are the service- level facilitators and barriers to 
the implementation of REACH- HF?
2. How do real- world patient and caregiver outcomes 
compare with those seen in a prior clinical trial?
3. What is the estimated economic (health and social) 
impact of implementing REACH- HF in Scotland?
Informed by process evaluation methodology, the study 
protocol detailed below is thus organised around four 
key components, which contribute to answering these 
questions:
 ► Fidelity of implementation: what was implemented 
and how closely this reflected what was intended (ie, 
the original REACH- HF intervention) (RQ1&2).
 ► Contextual factors: barriers to, and facilitators of, 
implementation, as perceived by the health profes-
sionals and service organisers involved; ‘background 
noise’ to implementation (RQ1).
 ► CR participant- related outcomes: whether, and to 
what extent, improvements in patient outcomes seen 
in the REACH- HF RCT are replicated (RQ2).
 ► Economic impact: health and social implementation 
costs (RQ3).
The study will be conducted across Scottish NHS 
Health Board CR services which, as early adopters of 
REACH- HF, will be designated as ‘Beacon Sites’. (The 
use of early adopters to model intervention implementa-
tion is itself one means of contributing to routinisation/
embedding of innovative practice.22) A national applica-
tion process followed promotion at national conferences, 
and contact letters to HF specialist nurses and CR leads. 
This resulted in recruitment of four sites across six NHS 
Health Boards to act as Beacon Sites: NHS Ayrshire and 
Arran; NHS Lanarkshire; NHS Forth Valley; and NHS 
Highland, Orkney, and Shetland (combined to act as one 
site due to small patient numbers). Sites were selected for 
their ability to commit to delivery of REACH- HF, and for 
geographic spread.
We will assess patient outcomes before and after admin-
istering the 12- week programme with 35 people with HF 
(140 total). Members of the HF team at each site will be 
interviewed. Detailed information of the costs and util-
isation of the provision of the REACH- HF programme 
will be collected. Given the ongoing COVID-19 crisis, the 
start of data collection for the study has been delayed, but 
will begin in November 2020. NHS Greater Glasgow and 
Clyde will act as study sponsor.
Sample and recruitment
The study will be conducted across Scottish NHS ‘Beacon 
Sites’. People with HF are eligible if they: are aged 18 
years or over; have a confirmed diagnosis of systolic 
(reduced ejection fraction) HF within the past 5 years; 
have experienced no deterioration of HF symptoms 
in the preceding 2 weeks resulting in hospitalisation or 
alteration of HF medication; and are deemed suitable for 
CR by their local clinical team. We will exclude anyone 
who: has undertaken CR in the preceding 12 months; has 
medical contraindications to exercise testing or training; 
is in a long- term care establishment, or unwilling/unable 
to travel to research assessments or accommodate home 
visits; is unable to understand the study information or 
unable to complete the outcome questionnaires. Patients 
with a caregiver will also be invited to participate. Patients 
with no caregiver, or whose caregivers do not wish to 
participate, are still eligible take part in the study.
Sites will recruit people with HF, using their usual 
means of CR referral to introduce the study. This is likely 
to include a variety of pathways such as: people with 
HF referred for CR from acute or primary care; review 
of patients held on site HF databases; and approaching 
people with HF at outpatient appointments/home visits. 
Potential participants will be provided with invitation 
letters, information sheets, and reply slips for both them 
and their caregiver (if applicable), and those interested 
in participation will be asked to instigate contact with 
the research team by returning the reply slips. Figure 1 
outlines the participation pathway for people with HF.
A maximum of 20 individual interviews will be 
conducted with health professionals involved in the 
delivery of SCOT:REACH- HF, near the end of the 
Figure 1 SCOT: Rehabilitation EnAblement in CHronic Heart Failure (REACH- HF) participant pathway.
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intervention period. These will include the trained facil-
itators (typically CR nurses or physiotherapists), as well 
as other key individuals involved in coordinating and 
commissioning CR (such as senior clinicians and service 
management). There may be some variation in partici-
pant roles due to the differing structures of local HF 
teams. We will use a combination of convenience and 
purposive sampling, offering the opportunity to partici-
pate to all those delivering REACH- HF, and those iden-
tified as having a key role in service planning, to ensure 
capture of diverse perspectives. A participant information 
sheet will be provided to all potential interviewees, and 
they will have adequate time to consider participation 
and ask questions about the interview process. Written 
consent will be obtained prior to face- to- face interviews. 
Where interviews are to be conducted by telephone, 
consent forms will be completed digitally and returned 
by email, and verbal consent recorded digitally.
The intervention
REACH- HF is a home- based, health professional- 
facilitated, 12- week CR programme supporting self- care 
in patients with HF. Three health professionals with CR 
and/or HF experience from each Beacon Site will attend 
a 2 days online REACH- HF training course facilitated by 
the Heart Manual Department, NHS Lothian (formerly 
a 3 days face- to- face training delivered in Edinburgh, the 
course has been adapted to accommodate current restric-
tions). Training focuses on the seven steps of successful 
facilitation of REACH- HF (in turn based on a person- 
centred care approach): (1) build rapport; (2) assess 
needs and build understanding of HF; (3) support self- 
management and progress monitoring; (4) discuss exer-
cise and well- being; (5) summarise and plan next steps; (6) 
review progress; (7) support long- term maintenance. As 
such, training includes sessions on psychology, behaviour 
change, physical activity, engaging caregivers and newly 
adapted components to address intervention delivery 
during the COVID-19 pandemic. Following training, 
facilitators are then asked to implement REACH- HF. 
The programme—described in detail elsewhere11 12—is 
outlined in box 1.
Measures/data collection
Patient and caregiver outcome data will be collected 
during an initial assessment appointment by a designated 
member of the Beacon Site team trained in data collec-
tion by the REACH- HF team, and via self- completion ques-
tionnaires (either postal or online, as per participants’ 
preference). Data will be collected at baseline—before 
commencing with the REACH- HF programme—and 
4 months following baseline, which coincides with the 
end of intervention delivery period (see figure 1).
Fidelity assessment
Facilitator–patient interactions (face- to- face and/
or phone) for 65 participants will be audio recorded. 
Recordings will be assessed using our established fidelity 
assessment checklist (described in detail elsewhere12). 
This 12- item checklist focuses on assessing inclusion 
by facilitators of key processes such as patient- centred 
communication, making a plan of action, and encour-
aging self- monitoring of progress. Facilitators will also 
be asked to complete a brief self- rated fidelity checklist 
after every session. This comprises questions on the same 
12 programme components and asks facilitators to rate 
occurrences of each feature (absent, minimal, some, 
sufficient, good, very good, excellent). An independent 
observer rating is resource intensive, while self- rated 
assessment may provide a pragmatic, real- world alterna-
tive to monitor delivery quality. We will also explore (in 
the interviews below) whether use of the checklist facil-
itates/encourages reflexive practice and, in doing so, 
quality of implementation.
Context
We seek to capture data on barriers to and facilita-
tors of implementation REACH- HF by interviewing 
health professionals at each Beacon Site. We anticipate 
conducting up to 20 individual interviews, which will 
be audio recorded and transcribed verbatim for anal-
ysis. Interviews will be conducted by CP face- to- face or 
by phone, as per the participant’s preference. Normal-
isation Process Theory (NPT)27 will be used as a theo-
retical framework to guide data collection, analysis and 
interpretation. A flexible topic guide—informed by the 
four constituent constructs of NPT (coherence, cognitive 
participation, collective action, reflexive monitoring), the 
existing literature on CR, and the key aims of the imple-
mentation study—will facilitate generation of rich data, 
Box 1 The Rehabilitation EnAblement in CHronic Heart 
Failure (REACH- HF) Intervention
 ► The Heart Failure Manual, which provides information about HF for 
the person with HF, to increase understanding of the condition and 
address common misconceptions.
 ► Information on and strategies for managing HF, and further relevant 
advice on, for example, managing lifestyle risk, managing depres-
sion and anxiety, and getting support from others.
 ► A choice of two exercise training programmes: a chair- based pro-
gramme (via DVD and online) and a walking programme; with a rec-
ommendation that these should be engaged in three times weekly, 
alongside general physical activity.
 ► A stress- management programme, with relaxation techniques (pro-
vided in the manual and in audio format) to help cope with anxiety 
and depression.
 ► A progress tracker designed to facilitate an individual’s learning 
from experience through self- monitoring of behaviour and symp-
toms. (this prompts help seeking as appropriate).
 ► A Family and Friends Resource to increase caregiver understanding 
of HF, to enable them to support the person with HF’s self- care and 
well- being.
 ► Face- to- face and telephone facilitation over 12 weeks by a 
health professional trained to deliver the REACH- HF programme. 
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as well as enabling capture of factors unanticipated by the 
research team (see online supplemental appendix 1).
Additional ad hoc contextual data from each site will 
be collated centrally (by CP) in one implementation 
log (Excel file) which will also capture overall ‘back-
ground noise’ to implementation (such as the impact of 
the COVID-19 pandemic) which will contribute to the 
contextual analysis.
CR participant-related outcomes
Data will be recorded in an electronic case report form 
(CRF), and participants will be offered the option of a 
paper self- completion questionnaire or a secure indi-
vidual link sent by email to complete the questionnaire 
online. At the baseline appointment, after obtaining 
written consent, Beacon Site teams will collect medical 
history from the participants’ hospital and primary care 
records, including: comorbidities (number and severity 
scored with Charlson Comorbidity Index); New York 
Heart Association class; HF aetiology; concomitant HF 
medication and presence of implantable HF devices.
Participants will provide detailed sociodemographic 
data (age, gender, ethnicity, weight, employment status, 
education level, smoking status) at baseline. The following 
participant outcomes will be assessed: disease- specific 
HRQoL measured using the MLHFQ; generic quality of 
life (five- dimension EuroQol (EQ- 5D- 5L) scale); psycho-
logical well- being (Hospital Anxiety and Depression 
Scale (HADS)); patient- reported outcome measure for 
cardiac rehab; hospitalisations and primary care contacts 
(number, reason, duration); adverse events (eg, skel-
etomuscular injury); health literacy (Health Literacy 
Questionnaire); and, if possible, exercise capacity via an 
incremental shuttle walk test (if face- to- face assessment 
possible). Caregiver outcomes are: generic quality of life 
(EQ- 5D- 5L); psychological well- being (HADS); Family 
Caregiver Quality of Life Scale questionnaire; Caregiver 
Burden Questionnaire HF; Caregiver Contribution to 
Self- care of HF Index questionnaire. The same outcomes 
will be collected at the 4- month follow- up.
Economic impact
Data will be collected to allow the costing of the 
REACH- HF intervention delivery. These will include time 
input from REACH- HF facilitators, supervision for facil-
itators, training costs for facilitators and consumables. 
Unit costs for resource use will be sought from national 
published or NHS sources. Data from each site will be 
recorded in the implementation log (excel file, as above).
Additionally, facilitators will be asked to complete a 
Facilitator Log for each participant. This log is a one- 
page pro forma designed to capture time, expenditure 
and any other resources required for the implementa-
tion of REACH- HF, as well as any adaptations made to 
the intervention for individual patients. As such, it will 
capture essential data for the fidelity and economic anal-
yses. Completed forms will be returned to the research 
team for data entry and analysis.
Data management
Data management will follow the principles of Good Clin-
ical Practice and supported by the University of Glasgow 
(UoG) Clinical Trials Unit (GCTU). An electronic CRF 
(eCRF) developed by the GCTU will capture all data noted 
above. Access to the eCRF will be restricted, via a study- 
specific web portal, with only authorised personnel able 
to make entries. RT or their designee will be responsible 
for all eCRF entries, and will confirm that data are accu-
rate, complete and verifiable. Entries from participant 
medical records will be made locally by Beacon Site staff 
trained by the research team. Where data are entered by 
the participant into a paper CRF, completed anonymous 
questionnaires will be returned by post to the University 
of Glasgow for data entry. Where completed by the partic-
ipant electronically, data will be entered directly into a 
participant- facing version of the eCRF. Where practical, 
data will be validated at the point of entry into the eCRF. 
Any additional data discrepancies will be flagged to RT 
and any changes recorded to maintain a complete audit 
trail (reason, date and who made the change). Data will 
be stored in a MS SQL Server database. Direct access to 
the study web portal will be granted, on request, to autho-
rised representatives of the sponsor, host institution and 
regulatory authorities to permit trial- related monitoring, 
audits and inspections.
The qualitative, fidelity and economic impact compo-
nents of the study will be conducted by UoG under the 
direction of RT. Transcription will be undertaken by a 
specialist service with whom UoG has an ongoing contrac-
tual arrangement and confidentiality agreement. All data 
(Excel files, audio recordings and anonymised transcripts, 
stored separately) will be kept for at least ten years in line 
with UoG Research Governance Framework Regulations 
for clinical research. Data will be stored confidentially 
on password- protected servers maintained on the UoG 
network. Anonymised data will be made available to other 
legitimate researchers on request, as per study consents.
The study will be overseen by the Project Manage-
ment Group (coapplicants) and Project Advisory 
Group (national CR experts)—see online supplemental 
appendix 2 for membership.
Data analysis
We require 130 participants to detect pre–post interven-
tion change in the MLFHQ scores to achieve the minimal 
important difference13 ≥5 points. This calculation is based 
on a MLHFQ SD of 24 points, within patient pre–post 
correlation (r=0.72) and attrition rate of ≤10% as seen in 
our multicentre RCTs refs. There is no formal sample size 
calculation for the number of caregivers participating in 
this study.
Fidelity
Fidelity data will be analysed by CP. Fidelity checklist 
scores will be collated at facilitator, site and total sample 
levels. We will present descriptive statistics (means, 
ranges), using the same analytic approach as the original 
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REACH- HF trial.13 In brief, the fidelity checklist uses an 
established 0–6 scale (Dreyfus scale of clinical skills acqui-
sition28) to rate clinical skills, and is anchored such that 
a score of three or more represents adequate delivery 
quality for each item. Fidelity outcomes will be compared 
with the REACH- HF RCT,13 and analysed alongside self- 
rated fidelity scores. Overall findings will be integrated 
with the context and CR participant- related outcome data 
findings.
CR participant-related outcomes
The primary analyses for primary and secondary quantita-
tive outcomes will based on a within- patient comparison 
in participants with complete outcome data at 4 months. 
We will examine the characteristics of any patients who 
withdraw, and conduct secondary analysis based on impu-
tation of their missing outcome data. All within- patient 
outcome comparisons will be presented as mean differ-
ence with 95% CI. The outcome effect size seen in the 
Beacon Sites will be indirectly compared with the changes 
found in the REACH- HF trial.13 Statistical analysis will be 
conducted by RT using STATA V.15. Descriptive statistics 
will be presented in order to describe study population 
characteristics.
Context
Verbatim transcripts (Word documents) will be pseud-
onymised (removing any potential indicators of personal 
identity or site) and uploaded into NVivo V.12 qualita-
tive software to facilitate data management. A coding 
framework will be developed, informed by the constructs 
of NPT noted above, and taking an approach informed 
by the Framework method.29 This approach will also for 
consideration of unanticipated issues.
Following this categorising stage, a further interpretive 
stage will see data examined across sources (professional 
role) and cases (sites). This will facilitate understanding of 
contextual factors shaping implementation of REACH- HF 
in context, and development of potential explanations 
for commonalities and differences between our findings 
and the previous RCT.
A subsequent integrative analysis will be conducted to 
bring together each analytic component (fidelity, context, 
CR participant- related outcomes). Integrative analysis 
will involve placing all relevant data in one integrative 
matrix and assessing for synergies which indicate our key 
findings, again guided by the NPT framework. Placing 
key findings in a matrix alongside those from the orig-
inal REACH- HF RCT will also facilitate understanding of 
the real- world effectiveness of the intervention. First stage 
coding, interpretation will be conducted by CP in consul-
tation with RT. Integrative analysis will be conducted by 
CP and RT with input from the project management 
group.
Economic impact
Economic analysis will focus on assessing the cost of the 
delivery of REACH- HF in the four Beacon Sites, that 
is, the additional (incremental) costs associated with 
delivery of the HF Manual, when added to usual care. 
Healthcare costs will be estimated using resource use data 
collected within the study, and unit costs for resource use 
from national published/NHS sources. Resource use is 
expected to consist of time input from REACH- HF facili-
tators, supervision for facilitators, training costs for facil-
itators and consumables (eg, intervention booklets for 
participants and facilitators). Data on facilitator time will 
be captured by facilitators at participant level, using the 
Facilitator Log described above. Economic analysis will be 
conducted by CP and RT alongside the main statistical 
analysis.
Patient public involvement (PPI)
People with HF and their caregivers had an extensive 
input into the development of the REACH- HF interven-
tion, and a substantial body of data on patient experiences 
has been generated through interviews with RCT partic-
ipants.13 14 We have established a standing PPI group for 
SCOT:REACH- HF led by TI, involving people with HF 
and their caregivers, who are independent of the study. 
Four meetings of the PPI group will be convened during 
the study to review participant- facing materials, advise 
on dissemination, and provide input on any participant 
related problems that may arise, such as recruitment and 
retention.
DISCUSSION
Approaches to implementation science are varied.23 We 
draw on MRC guidance on the evaluation of complex 
interventions which highlights that, while RCTs are 
viewed by many as the gold standard for demonstrating 
efficacy, they do not tell policy- makers or service commis-
sioners whether an intervention would produce the 
same outcomes in their context.26 A process evaluation 
approach produces understanding of implementation by 
assessing fidelity, context, and mechanisms of impact.25 
As the mechanisms of REACH- HF are explored else-
where,12 13 this study focuses on fidelity and context in the 
new delivery setting.
Most complex interventions would be expected to see 
some adaptation as they are transferred into real- world 
settings23 (variable by how much contextual factors have 
been considered in the design process). Indeed, some 
adaptability is in fact desirable in order to support effec-
tiveness.30 In order to assess if and how any adaptations 
might have impacted the overall integrity of the inter-
vention, it is vital to (1) have a clear picture ahead of 
implementation of what the active components of an 
intervention are, and (2) understand how closely delivery 
follows what is intended.30 Hence, we include above a 
description of the intervention’s constituent parts, and 
include in the study design a multipronged approach to 
assessing fidelity.
There are limitations on the degree to which novel 
interventions become embedded in routine clinical 
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practice. However, these limitations can be ameliorated 
by well- considered studies of implementation. By opera-
tionalising a tailored process evaluation methodology, we 
aim to assess such implementation, and the translation 
from RCT to real world, by paying particular attention 
to: fidelity to the intended programme, contextual factors 
shaping delivery, and how these may explain any differ-
ences measured in participant outcomes.
Our findings will inform potential larger scale roll- out 
of REACH- HF, offer guidance to policy- makers and CR 
commissioners, inform contextual adaptations, and facil-
itate diffusion and embedding of home- based CR for 
people with HF in the UK.
Strengths and limitations
This study will formally assess of the implementation of a 
novel home- based CR programme for HF in the context 
of NHS Scotland. It employs mixed methods which inte-
grates quantitative and qualitative approaches to under-
standing the implementation process. Moreover, our 
study will facilitate a communication channel between 
researchers and implementers, in order to support high- 
quality services for people with HF, and establish four 
key Beacon Sites that have the potential to model inter-
vention roll- out, should that be adopted more widely. 
Although limited to four sites geographical sites, these 
sites incorporate a wide range of settings including urban 
and rural populations. An additional strength is the 
adaptation of the study to the restrictions of the ongoing 
COVID-19 pandemic, and the potential to assess imple-
mentation of support for self- care for a potentially vulner-
able population.
ETHICS AND DISSEMINATION
The study has been given ethical approval by the West of 
Scotland Research Ethics Service (reference 20/WS/0038, 
approved 25 March 2020). Written informed consent will 
be obtained from all participants. The study is listed on 
the ISRCTN registry with study ID ISRCTN53784122. 
The research team will ensure that the study is conducted 
in accordance with both General Data Protection Regu-
lations and the University of Glasgow’s Research Gover-
nance Framework. Findings will be reported to the funder 
and shared with Beacon Sites, to facilitate service evalua-
tion, planning and good practice. To broaden interest in, 
and understanding of REACH- HF, we will seek to publish 
in peer- reviewed scientific journals and present at stake-
holder events, national and international conferences.
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APPENDIX 1 - SCOT:REACH-HF Interview Topic Guide  
 
Introduction:  
• Explain interview purpose / study aims  
• Emphasise no right/wrong answers, can decline to answer at any time 
• Opportunity for questions  
• Check consent, permission to record 
General:  
• Tell me a little about yourself (e.g. Job title, key roles/responsibilities)  
 
Starting out with REACH-HF 
• What was your first impression of REACH-HF?  
• Tell me about your experience of the facilitator training (if applicable)  
• Was the training sufficient to enable you to deliver REACH-HF? (PROMPT anything you would have 
liked to see done differently, added/left out, additional resources?) 
• Was there anything that made it easier/more difficult for you to take part in the training?  
• To what extent do you feel you started with a clear understanding of what you were being asked to 
do?  
Implementing REACH-HF (facilitators)  
• Tell me about when you first began delivering the intervention (PROMPT first patient session e.g.  
initial experiences, concerns, information gaps, confidence)  
• How has delivering REACH-HF differed from your usual way of working?  
• Was there anything that made it easier/more difficult for you to deliver the intervention? (PROMPT 
adequate support)   
• What did you see as being the main purpose of REACH-HF? (PROMPT has that changed?)  
• What, if any, changes did you make to how you delivered the intervention as time went on (e.g. to 
suit your way of working, or the patient’s needs)? (PROMPT for details)   
• How did you find the task of completing the post-session checklist (after recorded sessions)? 
(PROMPT e.g. useful, additional burden etc)  
 
Implementation of REACH-HF (non-facilitators)  
• Tell me about your impressions of how the delivery of REACH-HF went in your area  
• Was there anything that made it easier/more difficult for REACH-HF to be delivered in your area?  
• Can you tell me about any additional resources that were needed for REACH-HF? Or changes in 
roles/responsibilities?  
 
Embedding REACH-HF 
• How, if at all, has delivering REACH-HF changed the way you work? (PROMPT changes specific to 
home self-care; changes to way team works; if expect likely to be lasting change)  
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• How easy has it been to integrate REACH-HF into your usual work? (PROMPT good fit or not) 
• What changes, if any, would you make to REACH-HF to suit your way of working?  
• Of those you work with, who is it that’s driven REACH-HF forward? (PROMPT role, what they’ve done 
to support delivery; can include self)  
• In what way, if any, has implementing REACH-HF changed working relationships in your team?  
• Is there anything else that would make it easier for REACH-HF to become part of routine practice for 
your team? (PROMPT additional skills, training, support)  
• Are your team evaluating the impact of REACH-HF on your service? (PROMPT details)  
• What do you think is likely to be the future of REACH-HF in your service? (PROMPT likely to become 
routine practice?)  
 
Overall impressions of REACH-HF 
• To what extent do you feel that offering the intervention has been worthwhile?  
• When you’ve discussed as a team how REACH is going, can you tell me about how those 
conversations have gone? (PROMPT similarities/differences around e.g. aims, expected benefits as a 
mode of delivery) 
• What, if anything, do you see as being the value of the intervention:  
o For you 
o To your patients (if applicable)  
• Has the COVID-19 pandemic impacted your delivery of REACH-HF/CR?  
• What are your overall views on REACH-HF? (PROMPT anything not already noted)  
• Is there anything else you think it is important for the research team to know?  
 
Close 
• Any questions?  
• Feedback on interview?  
• Thank participant and close.  
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APPENDIX 2 – PROJECT MANAGEMENT GROUP AND INDEPENDENT 
ADVISORY GROUP MEMBERSHIP  
 
Project Management Group (To oversee the progress and delivery of the project) 
Prof Rod Taylor - Chief Investigator, University of Glasgow  
Dr Carrie Purcell – Project Manager, University of Glasgow  
Dr Hayes Dalal – Co-Applicant, REACH-HF co-Chief Investigator / Honorary Clinical Associate 
Professor, University of Exeter / Senior Clinical Researcher, Royal Cornwall Hospitals NHS Trust 
Dr Clare Murphy - Co-Applicant, NHS Greater Glasgow & Clyde / Scottish National Advisory 
Committee for Heart Disease – Heart Failure Subgroup Chair and Clinical Lead   
Dr Aynsley Cowie – Co-Applicant, Consultant Physiotherapist in Cardiology, NHS Ayrshire & Arran / 
BACPR Council Member  
Dr Tracy Ibbotson – Co-Applicant, Patient and Public Involvement and Engagement Lead, College of 
Medical, Veterinary and Life Sciences, University of Glasgow 
Prof John Cleland – Co-Applicant, Robertson Centre for Biostatistics, University of Glasgow  
Mrs Claire Kerr – Robertson Centre for Biostatistics, University of Glasgow 
 
 
Project Advisory Group (To provide independent advice and direction to the project) 
Ms Frances Divers – Cardiac Rehabilitation Champion, NHS Scotland (chair)  
Dr Edwin Jesudason – Cardiac Rehabilitation Clinical Lead, NHS Scotland 
Mr Richard Forsyth – Health Services Engagement Lead, British Heart Foundation Scotland  
Mr Nick Hartshorne-Evans – CEO, Pumping Marvellous (patient group)  
Ms Louise Taylor – Head of Services, Heart Manual Department, NHS Lothian  
Dr Hayes Dalal – REACH-HF co-Chief Investigator / Honorary Clinical Associate Professor, University 
of Exeter / Senior Clinical Researcher, Royal Cornwall Hospitals NHS Trust 
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Ms Helen Wilson, Head of Research, Heart Research UK (observer)  
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